Declared formulation50 mg T-38 + 25 mg GHK-Cu²⁺
SUPPLIER DECLARATIONRESEARCH PRODUCT
TelomeREGEN
75 mg
Declared formulationT-38 + GHK-Cu²⁺50 mg Pineal Gland Peptide T-38 + 25 mg GHK-Cu²⁺
A dual-layer Peptourbillon research formulation in the Lyoprester + EZnject system, prepared for controlled reconstitution inside a closed cartridge.
AVAILABLE NOWReady to add to cart
Price per pen890,00 zł
Total890,00 zł
- The dry formulation remains separated from the activation liquid
- The reconstitution liquid is integrated into a closed system
- Fewer manual reconstitution and liquid-transfer steps
- The dual-layer formulation and system are supplied as one set
AGEING-BIOLOGY & REGENERATION RESEARCH
These data concern individual components in specific experimental models, not the finished TelomeREGEN formulation or efficacy in humans.Indexed T-38 studies include cellular models of fibroblast-differentiation signalling and thymocyte maturation. GHK-Cu²⁺ has been studied in models of collagen synthesis and extracellular-matrix remodelling.
01 / PRODUCT DESCRIPTION
Formulation identity
According to the manufacturer specification, TelomeREGEN combines a peptide identified as Pineal Gland Peptide T-38 with GHK-Cu²⁺ in a dual-layer research formulation. The design supports investigation of identity, compatibility, post-reconstitution stability and the behaviour of both components in one system. It does not establish safety or efficacy in humans.
PRODUCT PASSPORT
Documentation first. Decision second.
Every parameter has its own status. Identity data is separated from supplier declarations and documents that must be assigned to a specific batch.
SUBVERIX™ / QUALITY RECORDLIVE STATUS
- Product
- TelomeREGEN 75 mg
- Format
- Dual-layer Peptourbillon / Lyoprester + EZnject
- Batch
- assigned before sale
Declared amount75 mg
SUPPLIER DECLARATIONDeclared purity≥98.8%
BATCH DOCUMENT REQUIREDPost-activation stabilityup to 90 days / 2–8°C (3°C recommended)
BATCH DOCUMENT REQUIREDDOCUMENT PACKAGE
Certificate of Analysis (CoA)BATCH DOCUMENT REQUIRED
Identity confirmationSUPPLIER DECLARATION
The manufacturer declaration describes TelomeREGEN as a dual-layer research formulation supplied in the Lyoprester + EZnject system.
- 50 mg Pineal Gland Peptide T-38 + 25 mg GHK-Cu²⁺, for a declared total formulation of 75 mg.
- The dual-chamber Lyoprester cartridge separates lyophilised material from 1 ml P-EARL liquid until activation.
- The material chamber is protected with argon and vacuum-sealed.
- The manufacturer identifies RP-HPLC and ESI-MS as analytical methods; purity and identity results require a batch-specific CoA.
This is a supplier declaration, not a batch certificate. SUBVERIX™ keeps the CoA status pending until the document is received and reviewed.
Manufacturer specification — TelomeREGEN 75 mgA parameter is marked as verified only after its source document has been reviewed. Missing documentation is never replaced by a marketing promise.
02 / TELOMEREGEN
Why this format?
Dual-layer formulation
T-38 and GHK-Cu²⁺ are described as two parts of one research formulation intended for analysis after activation.
Dual-chamber format
The dry material and reconstitution liquid remain separated until system activation.
Closed fluid path
The system reduces manual vial opening and solvent transfer between separate containers.
Traceable set
The cartridge, EZnject system and documentation should be assigned to a specific product batch.
03 / EZNJECT
What is included
- dual-chamber Lyoprester cartridge with a declared 75 mg formulation
- 1 ml P-EARL reconstitution liquid declared by the supplier
- disposable EZnject system with a supplier-declared micro-indexed mechanism
- batch-identification information; final set contents will be confirmed before sale
04 / SPECIFICATION
Technical data
- Type
- Dual-layer Peptourbillon
- Formulation
- 75 mg
- Components
- 50 mg T-38 + 25 mg GHK-Cu²⁺
- Format
- Lyoprester + EZnject
- Declared purity
- ≥98.8% — batch CoA required
Quality verification
The manufacturer declares RP-HPLC, ESI-MS and cell-based testing. Parameters require confirmation by a certificate of analysis and batch-specific documentation before they are presented as verified SUBVERIX™ data.
Storage and stability
The manufacturer declares room-temperature stability of the unactivated cartridge and up to 90 days after activation when refrigerated at 2–8°C; the recommended temperature is 3°C. These conditions require a formulation- and batch-specific stability report.
Intended use
Strictly for professional in vitro laboratory research or, where permitted by law and an approved protocol, in vivo research at an authorised institution. The product is not intended for human use.
08 / EVIDENCE
Sources and documentation
The evidence map separates manufacturer specifications, T-38 research and GHK-Cu²⁺ research. No published study of the finished TelomeREGEN formulation was identified, so component data are not presented as proof of the complete product.MANUFACTURER SPECIFICATION — TelomeREGEN 75 mg PRIMARY STUDY / T-38 — fibroblast differentiation signalling PRIMARY STUDY / T-38 — thymocyte differentiation models PRIMARY STUDY / GHK-Cu — MMP-2 expression in fibroblasts PRIMARY STUDY / GHK-Cu — collagen synthesis in fibroblasts How the dual-chamber cartridge works Peptide stability Back to shop